Opendata, web and dolomites


CHECKPOINTS IN CHECK: Novel Chemical Toolbox for Local Cancer Immunotherapy

Total Cost €


EC-Contrib. €






 CHEMCHECK project word cloud

Explore the words cloud of the CHEMCHECK project. It provides you a very rough idea of what is the project "CHEMCHECK" about.

immunotherapeutic    break    advancing    limited    patient    risk    form    vaccines    multifunctional    acting    multimodal    barrier    inhibitors    immunological    individual    toxicity    cancer    immunotherapy    subset    release    functionalized    hypostasize    modimab    obtain    molecular    effector    locally    immunosuppressive    tumour    cells    systemic    care    fragments    angles    therapeutic    vitro    tear    uncharted    immune    attacking    back    symbiotic    multiple    goes    patients    extremely    team    chemistry    synergistic    wellbeing    spotlights    macrophages    utilizing    endeavour    generate    checkpoints    checkpoint    cell    explore    territories    recognise    autoimmunity    eliminate    unhampered    benefits    toolbox    immunomodulation    chemical    single    evades    anti    me    dendritic    conditional    regime    dramatically    vivo    attack    multidisciplinary    blocking    treatment    breakthroughs    mechanisms    put    simultaneously    microenvironment    generating    clinical    tools    autoimmune    antibody    educate    local   

Project "CHEMCHECK" data sheet

The following table provides information about the project.


Organization address
postcode: 6525 EZ

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website
 Total cost 1˙500˙000 €
 EC max contribution 1˙500˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2015-STG
 Funding Scheme ERC-STG
 Starting year 2016
 Duration (year-month-day) from 2016-07-01   to  2021-06-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 


 Project objective

Cancer evades the immune system by generating an immunosuppressive tumour-microenvironment through various mechanisms to enable unhampered growth. Recent breakthroughs in blocking one of these mechanisms – the so called ‘immune checkpoints’ – put cancer immunotherapy back in the spotlights. Although promising, clinical benefits of these checkpoint inhibitors as single treatment has been limited to a subset of patients and goes along with unwanted systemic autoimmune toxicity. I hypostasize, that attacking the tumour microenvironment from multiple immunological angles simultaneously by local, conditional, and multimodal immunomodulation will greatly improve success of cancer immunotherapy and patient wellbeing. To achieve this, I will develop a highly defined synergistic chemistry-based molecular therapeutic toolbox to specifically attack cancer, acting on effector T cells, macrophages as well as tumour cells simultaneously. In this highly multidisciplinary endeavour I will (i) generate novel multifunctional dendritic cell targeted anti-cancer vaccines to ‘educate’ the patient’s immune system to recognise the tumour, (ii) I will develop conditional, targeted immune checkpoint inhibitors to release the immunosuppressive break specifically within the tumour microenvironment without the risk of autoimmunity and (iii) I will generate chemical tools to locally eliminate the tumour-associated macrophages to tear down a major immunosuppressive barrier. I will do so utilizing the novel ModimAb technology which I developed to obtain functionalized antibody fragments. These individual therapeutic tools will allow me and my research team to explore uncharted tumour immunological territories in vitro as well as in vivo, greatly advancing the field of cancer immunotherapy. But above all, together they will form a highly dedicated symbiotic immunotherapeutic regime which will be extremely effective without systemic side effects, dramatically improving patient care.


year authors and title journal last update
List of publications.
2019 Maksim V. Baranov, Frans Bianchi, Anastasiya Schirmacher, Melissa A.C. van Aart, Sjors Maassen, Elke M. Muntjewerff, Ilse Dingjan, Martin ter Beest, Martijn Verdoes, Samantha G.L. Keyser, Carolyn R. Bertozzi, Ulf Diederichsen, Geert van den Bogaart
The Phosphoinositide Kinase PIKfyve Promotes Cathepsin-S-Mediated Major Histocompatibility Complex Class II Antigen Presentation
published pages: 160-177, ISSN: 2589-0042, DOI: 10.1016/j.isci.2018.12.015
iScience 11 2020-02-24
2018 Liping Qiu, Michael Valente, Yusuf Dolen, Eliezer Jäger, Martin ter Beest, Liyan Zheng, Carl G. Figdor, Martijn Verdoes
Endolysosomal-Escape Nanovaccines through Adjuvant-Induced Tumor Antigen Assembly for Enhanced Effector CD8 + T Cell Activation
published pages: 1703539, ISSN: 1613-6810, DOI: 10.1002/smll.201703539
Small 14/15 2020-02-24
2018 Bob J. Ignacio, Tyler J. Albin, Aaron P. Esser-Kahn, Martijn Verdoes
Toll-like Receptor Agonist Conjugation: A Chemical Perspective
published pages: 587-603, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.7b00808
Bioconjugate Chemistry 29/3 2020-02-24
2019 Floris van Dalen, Marleen van Stevendaal, Felix Fennemann, Martijn Verdoes, Olga Ilina
Molecular Repolarisation of Tumour-Associated Macrophages
published pages: 9, ISSN: 1420-3049, DOI: 10.3390/molecules24010009
Molecules 24/1 2020-02-24
2019 Dion Voerman, Marjolein Schluck, Jorieke Weiden, Ben Joosten, Loek J. Eggermont, Tuur van den Eijnde, Bob Ignacio, Alessandra Cambi, Carl G. Figdor, Paul H. J. Kouwer, Martijn Verdoes, Roel Hammink, Alan E. Rowan
Synthetic Semiflexible and Bioactive Brushes
published pages: 2587-2597, ISSN: 1525-7797, DOI: 10.1021/acs.biomac.9b00385
Biomacromolecules 20/7 2020-02-24
2019 Johan M.S. van der Schoot, Felix L. Fennemann, Michael Valente, Yusuf Dolen, Iris M. Hagemans, Anouk M.D. Becker, Camille M. Le Gall, Duco van Dalen, Alper Cevirgel, J. Armando C. van Bruggen, Melanie Engelfriet, Marieke F. Fransen, Tomislav Caval, Arthur E.H. Bentlage, Maaike Nederend, Jeanette H.W. Leusen, Albert J.R. Heck, Gestur Vidarsson, Carl G. Figdor, Martijn Verdoes*, Ferenc A. Scheeren
Functional diversification of hybridoma produced antibodies by CRISPR/HDR genomic engineering.
published pages: , ISSN: , DOI: 10.1101/551382
2019 Marjolein Schluck, Roel Hammink, Carl G. Figdor, Martijn Verdoes, Jorieke Weiden
Biomaterial-Based Activation and Expansion of Tumor-Specific T Cells
published pages: , ISSN: 1664-3224, DOI: 10.3389/fimmu.2019.00931
Frontiers in Immunology 10 2020-02-24
2019 Felix L. Fennemann, I. Jolanda M. de Vries, Carl G. Figdor, Martijn Verdoes
Attacking Tumors From All Sides: Personalized Multiplex Vaccines to Tackle Intratumor Heterogeneity
published pages: , ISSN: 1664-3224, DOI: 10.3389/fimmu.2019.00824
Frontiers in Immunology 10 2020-02-24

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CHEMCHECK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CHEMCHECK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)


The Mass Politics of Disintegration

Read More  


The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

GTBB (2019)

General theory for Big Bayes

Read More